New Gel Stent Device Could Be A Better Surgical Option for Glaucoma Patients

The Reality of This “Future Tech”

This technology was initially developed several years ago. In 2014, human trials in the efficacy of gel stents began, and in 2015 Dr. Varma reported the results of those trials. One year after implantation, Varma found patient eye pressure was reduced by 44% and their medication was reduced by 65%. In November 2016, Allergan, the manufacturer of the XEN system, received FDA approval for the treatments.2

While it is still too early to know how effective the XEN device will be in treating those with glaucoma, it is an exciting development and another step on the path towards quicker, easier, and less expensive treatment options for those suffering with this degenerative disease.

With the support of organizations like Glaucoma Research Foundation, researchers are able to continue searching for a cure. Learn how your generosity can help that search.

1 “USC Roski Eye Institute Director Helps Breakthrough Glaucoma Treatment Come to the U.S. as Allergan Receives FDA Clearance for XEN® Gel Stent.” USC Roski Eye Institute. N.p., n.d. Web. 03 Jan. 2017.

2 Snelling, Sherri. “Breakthrough refractory glaucoma treatment cleared by FDA after clinical trials.” Keck School of Medicine of USC. N.p., 30 Nov, 2016. Web. 06 Jan. 2017.

Leave a Reply

Your email address will not be published. Required fields are marked *